Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:CORT NASDAQ:JAZZ NASDAQ:RPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.25B0.54510,939 shs506,617 shsCORTCorcept Therapeutics$69.360.0%$70.57$33.66▼$117.33$7.31B0.29598,470 shs967,021 shsJAZZJazz Pharmaceuticals$129.50+1.2%$116.68$95.49▼$148.06$7.86B0.24726,655 shs718,357 shsRPRXRoyalty Pharma$36.07-2.2%$36.34$24.05▼$38.00$21.04B0.583.16 million shs9.23 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+3.21%+19.99%+11.85%+30.99%CORTCorcept Therapeutics0.00%-0.52%-2.97%-0.34%+100.35%JAZZJazz Pharmaceuticals0.00%+1.37%+15.54%+16.53%+19.20%RPRXRoyalty Pharma0.00%+0.25%-2.54%+6.78%+23.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.25B0.54510,939 shs506,617 shsCORTCorcept Therapeutics$69.360.0%$70.57$33.66▼$117.33$7.31B0.29598,470 shs967,021 shsJAZZJazz Pharmaceuticals$129.50+1.2%$116.68$95.49▼$148.06$7.86B0.24726,655 shs718,357 shsRPRXRoyalty Pharma$36.07-2.2%$36.34$24.05▼$38.00$21.04B0.583.16 million shs9.23 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+3.21%+19.99%+11.85%+30.99%CORTCorcept Therapeutics0.00%-0.52%-2.97%-0.34%+100.35%JAZZJazz Pharmaceuticals0.00%+1.37%+15.54%+16.53%+19.20%RPRXRoyalty Pharma0.00%+0.25%-2.54%+6.78%+23.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.13Buy$177.8642.09% UpsideCORTCorcept Therapeutics 3.00Buy$134.5093.92% UpsideJAZZJazz Pharmaceuticals 2.88Moderate Buy$178.6737.97% UpsideRPRXRoyalty Pharma 3.33Buy$48.0033.07% UpsideCurrent Analyst Ratings BreakdownLatest JAZZ, AXSM, RPRX, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.008/29/2025JAZZJazz PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$162.00 ➝ $185.008/28/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$162.00 ➝ $163.008/28/2025JAZZJazz PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$145.00 ➝ $151.008/28/2025JAZZJazz PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $205.008/28/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$202.008/20/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$202.008/15/2025JAZZJazz PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/6/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$165.00 ➝ $162.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$173.00 ➝ $176.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M16.19N/AN/A$1.18 per share106.08CORTCorcept Therapeutics$675.04M10.83$1.24 per share55.85$6.49 per share10.69JAZZJazz Pharmaceuticals$4.07B1.93$30.33 per share4.27$67.72 per share1.91RPRXRoyalty Pharma$2.31B9.12$4.19 per share8.60$17.56 per share2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A44.39N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)CORTCorcept Therapeutics$141.21M$1.1361.3837.49N/A18.51%20.10%16.20%10/29/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A6.928.03-9.91%5.02%1.73%11/5/2025 (Estimated)RPRXRoyalty Pharma$858.98M$1.7320.857.422.3544.23%25.54%14.11%11/5/2025 (Estimated)Latest JAZZ, AXSM, RPRX, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025RPRXRoyalty Pharma$1.10$1.14+$0.04$0.05$750.06 million$578.67 million8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billion8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/31/2025Q2 2025CORTCorcept Therapeutics$0.23$0.29+$0.06$0.29$199.40 million$194.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.882.44%N/A50.87%5 YearsLatest JAZZ, AXSM, RPRX, and CORT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/18/2025RPRXRoyalty Pharmaquarterly$0.222.48%8/15/20258/15/20259/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51CORTCorcept TherapeuticsN/A3.062.98JAZZJazz Pharmaceuticals1.171.621.37RPRXRoyalty Pharma0.741.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CORTCorcept Therapeutics93.61%JAZZJazz Pharmaceuticals89.14%RPRXRoyalty Pharma54.35%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%CORTCorcept Therapeutics20.80%JAZZJazz Pharmaceuticals4.30%RPRXRoyalty Pharma18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableCORTCorcept Therapeutics300105.37 million83.46 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableRPRXRoyalty Pharma80583.17 million472.95 millionOptionableJAZZ, AXSM, RPRX, and CORT HeadlinesRecent News About These CompaniesEventide Asset Management LLC Has $27.41 Million Position in Royalty Pharma PLC $RPRXSeptember 6 at 8:43 AM | marketbeat.comRoyalty Pharma PLC $RPRX Stock Holdings Decreased by Cutter Capital Management LPSeptember 6 at 7:35 AM | marketbeat.comPanagora Asset Management Inc. Sells 14,226 Shares of Royalty Pharma PLC $RPRXSeptember 6 at 5:21 AM | marketbeat.comRoyalty Pharma PLC $RPRX Shares Sold by AlTi Global Inc.September 5 at 6:55 AM | marketbeat.comRoyalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 4 at 4:15 PM | globenewswire.comAdage Capital Partners GP L.L.C. Sells 10,718,321 Shares of Royalty Pharma PLC $RPRXSeptember 4 at 7:42 AM | marketbeat.comRoyalty Pharma PLC $RPRX Shares Sold by Evergreen Capital Management LLCSeptember 4 at 5:13 AM | marketbeat.comWalleye Capital LLC Has $354,000 Stock Position in Royalty Pharma PLC $RPRXSeptember 4 at 3:57 AM | marketbeat.comRoyalty Pharma PLC $RPRX Shares Sold by Canada Pension Plan Investment BoardSeptember 3, 2025 | marketbeat.comIeq Capital LLC Acquires 27,597 Shares of Royalty Pharma PLC $RPRXSeptember 3, 2025 | marketbeat.comRoyalty Pharma PLC $RPRX Shares Sold by BNP Paribas Financial MarketsSeptember 3, 2025 | marketbeat.comRoyalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured NotesSeptember 2, 2025 | globenewswire.comRoyalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 MillionSeptember 2, 2025 | globenewswire.comZenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 MillionSeptember 2, 2025 | globenewswire.comOMERS ADMINISTRATION Corp Purchases 8,453 Shares of Royalty Pharma PLC $RPRXSeptember 2, 2025 | marketbeat.comAmerican Century Companies Inc. Has $2.32 Million Position in Royalty Pharma PLC $RPRXSeptember 2, 2025 | marketbeat.comGMT Capital Corp Has $74.01 Million Holdings in Royalty Pharma PLC $RPRXSeptember 1, 2025 | marketbeat.comMagnetar Financial LLC Buys Shares of 161,496 Royalty Pharma PLC $RPRXSeptember 1, 2025 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Raised to "Buy" at Wall Street ZenSeptember 1, 2025 | marketbeat.comCompound Planning Inc. Invests $244,000 in Royalty Pharma PLC $RPRXAugust 31, 2025 | marketbeat.comDoes Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?August 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAZZ, AXSM, RPRX, and CORT Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$125.17 +0.76 (+0.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$126.23 +1.06 (+0.85%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Corcept Therapeutics NASDAQ:CORT$69.36 -0.01 (-0.01%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$69.22 -0.14 (-0.20%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Jazz Pharmaceuticals NASDAQ:JAZZ$129.50 +1.48 (+1.16%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$128.81 -0.69 (-0.53%) As of 09/5/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Royalty Pharma NASDAQ:RPRX$36.07 -0.83 (-2.25%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$35.98 -0.09 (-0.24%) As of 09/5/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
